Dublin, May 22, 2019 (GLOBE NEWSWIRE) — The “Overview of the Japanese CRO Market 2019” report has been added to ResearchAndMarkets.com’s offering.
This report takes an overview of the CRO market in Japan. By reading this report, readers will understand the overall picture of the Japanese CRO market, including the market size trends, major CRO players, in addition to the competitive differences between local and global CROs.
The Japanese CRO market has been expanding in recent years, and it reached over 180 Yen billion in 2017.
When the market is broken down by functional services, monitoring accounted for 58% of the total market and followed by data management with 14%.
Phase III occupies 42.2%, followed by PMS; post-marketing surveillance with 9.9%, and phase II with 9.2%.
There is still some room for pharma to outsource clinically related works. The rate of outsourcing will also increase a little in the coming years. Furthermore, the shortage of operational resources in pharma in the last 5 years enhanced the outsourcing works from pharma to CROs.
Japan may face a situation in which it loses some clinical trials to other regions, especially China in the near future. As trials shift to global studies from local ones, this tendency will increase over time.
Clients have introduced a preferred/strategic partnership model with top 6 CROs mentioned earlier, especially IQVIA. IQVIA had to turn down many of projects due to resource constraint in the last 5 years, and other CROs could reap the benefits, taking over those projects from IQVIA. The resource issue in CROs is now quickly resolving, as pharma is cutting many jobs and people are flowing into CROs. Due to better capability in global CROs, clients are shifting to selected global CROs, and this will increase over time.
Key Topics Covered:
- Definition of CRO Market
- Clinical Trial Trend
- Challenges when conducting clinical trails in Japan
- CRO market size
- CRO market breakdown by service
- CRO market breakdown by phase
- Key Industry Association
- Major CRO companies
- Top 6 CROs
- A2 Healthcare
- M3 Group
- Other players globally
- Syneos Health
- Clinical Trial Trend
- Increasing Outsourcing in Pharma
- Shift of Multinational Clinical Trials
- Contrast of Japanese and foreign CROs
- Strategic partnership model
- Future outlook
For more information about this report visit https://www.researchandmarkets.com/r/b4s5jq
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Drug Discovery